Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07360314 · ClinicalTrials.gov registry record · Phase 1
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by EMD Serono Research & Development Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 138
- Enrollment target
- 8
- Study locations
NCT07360314: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by EMD Serono Research & Development Institute.
NCT07360314 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by EMD Serono Research & Development Institute. The registered enrollment target is 138 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (30% lower). The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07360314, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by EMD Serono Research & Development Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 138 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), epithelial ovarian carcinoma (EOC), squamous cell carcinoma of the head and neck (SCCHN), pancreatic ductal adenocarcinoma (PDAC), and gastric cancer (GC).
Conditions Studied
Interventions
- DRUG M7437
Study Locations (8)
Other
- Princess Margaret Cancer Centre - Toronto
- BC Cancer - Vancouver - BC Cancer Agency - Vancouver
- National Cancer Center Hospital - Tokyo
- NEXT Madrid - Hospital Universitario Quironsalud Madrid - Madrid
Texas
- NEXT Houston - Galveston
- NEXT Oncology - PARENT - San Antonio
Connecticut
- Yale University - Yale University School of Medicine - New Haven
North Carolina
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center - Huntersville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2026-02-13 |
| Est. Completion | 2029-03-28 |
| Phase | Phase 1 |
What NCT07360314 shows while recruiting
NCT07360314 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which M7437 is the first listed.
NCT07360314 lists 8 locations in 4 states (Other, Texas, Connecticut).
Frequently Asked Questions
What is clinical trial NCT07360314 about?
NCT07360314 is a clinical study titled "Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors". The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-...
What is the current status of trial NCT07360314?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 138 participants. The study started on 2026-02-13. Estimated completion is 2029-03-28.
What conditions does trial NCT07360314 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT07360314?
The interventions under investigation include: M7437 (DRUG).
Who is sponsoring clinical trial NCT07360314?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07360314 being conducted?
This trial has 8 study locations across Connecticut, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07360314's enrollment target sits among peer trials
138 62nd of 144 higher than 83 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI